JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Mancuso, Roberta ^a   Saresella, Marina ^a   Hernis, Ambra ^a   Marventano, Ivana ^a   Ricci, Cristian ^a   Agostini, Simone ^a,b   Rovaris, Marco ^a   Caputo, Domenico ^a   Clerici, Mario ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cell mediated immunity; MS; Natalizumab

Indexed keywords

LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATALIZUMAB; PROTEIN VP1;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DEGRANULATION; FEMALE; HUMAN; HUMAN CELL; JC VIRUS; LYMPHOCYTE COUNT; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; VIRUS DETECTION; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA, VIRAL; FEMALE; GRANZYMES; HUMANS; IMMUNITY; IMMUNOLOGIC MEMORY; JC VIRUS; LONGITUDINAL STUDIES; LYMPHOCYTE SUBSETS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MULTIPLE SCLEROSIS; PERFORIN; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 84870656461     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-248     Document Type: Article

References (39)

1. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.
2. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-80. 10.1056/NEJMoa1107829, 22591293.
3. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 2009, 65:367-377. 10.1002/ana.21630, 19399841.
4. Ransohoff RM. " Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007, 259:50-52. 10.1016/j.jns.2006.04.011, 17521672.
5. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 111:3893-3895. 10.1182/blood-2007-10-120329, 18235044.
6. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab natalizumab and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009, 10:816-824. 10.1016/S1470-2045(09)70161-5, 19647202.
7. Tan CS, Ellis LC, Wuthrich C, Ngo L, Broge TA, Saint-Aubyn J, Miller JS, Koralnik IJ. JC Virus Latency in the Brain and Extraneural Organs of Patients with and without Progressive Multifocal Leukoencephalopathy. J Virol 2010, 84:9200-9209. 10.1128/JVI.00609-10, 2937633, 20610709.
8. Andreoletti L, Lescieux A, Lambert V, Si-Mohamed A, Matta M, Wattré P, Belec L. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol 2002, 66:1-7. 10.1002/jmv.2103, 11748651.
9. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009, 73:1551-1558. 10.1212/WNL.0b013e3181c0d4a1, 2777072, 19901246.
10. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002, 186:S180-186. 10.1086/344280, 12424695.
11. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz S. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010, 68:304-310. 10.1002/ana.22107, 20737514.
12. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303. 10.1002/ana.22128, 20737510.
13. Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. J Neuroimmune Pharmacol 2012,
14. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009, 199:837-46. 10.1086/597126, 19434930.
15. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL. Association of prolonged survival in HLA-A2 progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002, 168:499-504.
16. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004, 127:1970-1978. 10.1093/brain/awh215, 15215217.
17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302. 10.1002/ana.22366, 3084507, 21387374.
18. Delbue S, Sotgiu G, Fumagalli D, Valli M, Borghi E, Mancuso R, Marchioni E, Macerati R, Ferrante P. A case of a PML patient with four different JC virus TCR rearrangements in CSF, blood, serum and urine. J Neurovirol 2005, 11:51-57. 10.1080/13550280590900382, 15804959.
19. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001, 75:3483-3487. 10.1128/JVI.75.7.3483-3487.2001, 114143, 11238876.
20. Magri G, Clerici M, Dall'Ara P, Biasin M, Caramelli M, Casalone C, Giannino ML, Longhi R, Piacentini L, Della Bella S, Gazzuola P, Martino PA, Pollera C, Puricelli M, Servida F, Crescio I, Boasso A, Ponti W, Poli G. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 2005, 23:2862-2868. 10.1016/j.vaccine.2004.11.067, 15780734.
21. Du Pasquier RA, Clark KW, Smith PS, Joseph JT, Mazullo JM, De Girolami U, Letvin NL, Koralnik IJ. Favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy correlates with JCV-specific cellular immune response. J Neurovirol 2001, 7:318-322. 10.1080/13550280152537175, 11517410.
22. Du Pasquier RA, Schmitz JE, Jean-Jacques J, Zheng Y, Gordon J, Khalili K, Letvin NL, Koralnik IJ. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004, 78:10206-10210. 10.1128/JVI.78.18.10206-10210.2004, 514969, 15331755.
23. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78. 10.1016/S0022-1759(03)00265-5, 14580882.
24. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010, 9:264-272. 10.1016/S1474-4422(10)70006-5, 20117055.
25. Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry 2010, 81:1345-1350. 10.1136/jnnp.2009.201079, 20547618.
26. Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, Frias C, Perez-Trallero E, Ryschkewitsch CF, Stoner GL. Genotypes of JC virus in East Central and Southwest Europe. J Gen Virol 2001, 82:1221-1231.
27. Polo C, Perez JL, Mielnichuck A, Fedele CG, Niubò J, Tenorio A. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004, 10:640-644. 10.1111/j.1469-0691.2004.00882.x, 15214877.
28. Pagani E, Delbue S, Mancuso R, Borghi E, Tarantini L, Ferrante P. Molecular Analysis of JCV genotipes circulating among the italian population. J Neurovirol 2003, 9:559-566.
29. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R, Calvo MG, Ferrante P. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 2007, 79:408-412. 10.1002/jmv.20829, 17311343.
30. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007, 68:985-990. 10.1212/01.wnl.0000257832.38943.2b, 17389301.
31. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009, 361:1067-1074. 10.1056/NEJMoa0904267, 3077718, 19741227.
32. Sadiq SA, Puccio LM, Brydon EW. JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 2010, 257:954-958. 10.1007/s00415-009-5444-4, 20052484.
33. Gallia GL, Houff SA, Major EO, Khalili K. JC virus infection of lymphocytes- revisited. J Infect Dis 1997, 176:1603-1609. 10.1086/514161, 9395374.
34. Jensen PN, Major EO. Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. J Leukoc Biol 1999, 65:428-438.
35. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010, 68:384-391. 10.1002/ana.22137, 20818792.
36. Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012, 18:143-52. 10.1177/1352458511435105, 22312009.
37. Sweet TM, Del Valle L, Khalili K. Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol 2002, 191:249-256. 10.1002/jcp.10096, 12012320.
38. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, Petry H, Weber T, Luke W. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001, 49:636-642. 10.1002/ana.1004, 11357954.
39. Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, Lazzarin A, Weber T, Cinque P. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000, 30:95-99. 10.1086/313598, 10619739.